Gyros Protein Technologies debuts test for impurities in E. coli systems

New product is a host cell protein (HCP) kit for automated impurity analysis of biotherapeutics expressed in E. coli systems

Gyros Protein Technologies has introduced a new host cell protein (HCP) kit for automated impurity analysis of biotherapeutics expressed in E. coli systems. This test is a critical step in ensuring the efficacy and safety of the drug molecule.

Gyros supplies automated nanoliter-scale immunoassays and is a provider of peptide synthesisers and reagents. This new kit is the latest addition to the company’s growing portfolio.

The new kit is optimised for use in Gyrolab systems. It has been developed as part of a licensing and supply agreement with Cygnus Technologies (part of Maravai LifeSciences), incorporating their industry standard E. coli HCP antibodies and other reagents.

Jasmine Gruia-Gray, SVP of Marketing at Gyros Protein Technologies, said: “Gyrolab E. coli HCP Kit is a valuable addition to our growing portfolio of bioprocess kits, which help our customers to rapidly achieve critical analytical answers.”

Gyros has established expertise in bioprocess development, through its Gyrolab platforms and ready-to-use kits for CHO-HCP, Protein A impurity analyses, and IgG titer determinations.

Gyrolab systems provide automated immunoassays for impurities such as HCPs, with a fast turn-around time, broad dynamic ranges and high reproducibility, making it an ideal technology to support all phases of biotherapeutic bioprocess development and production.

Companies